Skip to content
value.today
CorMedix Inc. logo

CorMedix Inc.

CRMD
$652 Mmarket cap on Oct 29, 2026+232.8% since Jan 2024
Compare
World rank
#11,419
Revenue
$312 M
For year ending December-2025
Net income
$163 M
52.3% margin
SEC filing
Employees
191
As of February 28, 2026
SEC filing

CorMedix Inc. in brief

CorMedix Inc. is a listed company in the Biotechnology industry, based in Parsippany, New Jersey, USA. It was founded in 2006. Its market value was $652 M on 29 October 2026, which makes it the 11,419th largest listed company in the world and the 2,363rd largest in the USA on this site. In the year to December 2025 it had sales of $312 M and a net profit of $163 M, about 52 cents of profit for every dollar of sales. It employs about 191 people and Joseph Todisco is its chief executive. Its largest product and service lines by sales in 2025 were DefenCath (83%), Melinta Portfolio (15%) and Contract revenue (2%). Its shares trade under the symbol CRMD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CorMedix Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration.

On August 29, 2025, the Company acquired Melinta Therapeutics, LLC, a Delaware limited liability company, which expanded the Company’s team, commercial platform and increased the commercial portfolio with six marketed, hospital- and clinic-focused infectious disease products, comprised of REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), and BAXDELA® (delafloxacin), as well as an additional well-established cardiovascular product, TOPROL-XL® (metoprolol succinate). The Melinta Portfolio supports a multi-channel strategy of delivering anti-infectives for serious gram-positive, gram-negative and fungal infections within hospitals and the hospital ecosystem, including emergency departments, outpatient clinics and home infusion care, and provides synergy opportunities to drive growth for DefenCath.

From the company's annual report filed with the US SEC: read the report

CorMedix Inc. timeline

3 events, 2006–2025
  1. 2006
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2025
  6. 💰
    Record revenue of $312 million
    FY2025, the highest of the 7 years on record.

Events of CorMedix Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$176 M$352 M$528 M$704 M2020202120222023202420252026

World rank over time

▲ up 4,893 places since 2020
2020-01-01: #16340#16,34020202021-01-01: #14733#14,73320212022-01-07: #19224#19,22420222022-12-25: #18910#18,91020222023-07-30: #17168#17,16820232024-01-05: #18014#18,01420242026-03-08: #6954#6,95420262026-08-01: #11593#11,59320262026-09-18: #11732#11,73220262026-10-29: #11447#11,4472026

Rank in USA: #3,320 (Jan 2020) · #3,116 (Jan 2021) · #3,909 (Jan 2022) · #3,835 (Dec 2022) · #3,461 (Jul 2023) · #3,265 (Jan 2024) · #1,222 (Mar 2026) · #2,435 (Aug 2026) · #2,395 (Sep 2026) · #2,365 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
10.2×
Price / sales (TTM)
1.6×
Price / book
1.6×
Free cash flow yield
26.5%
Net margin (TTM)
15.5%
Operating margin
48.2%
Return on equity
15.8%
Liabilities / assets
50.9%
Revenue growth
+617.1%
R&D / revenue
6.2%
Revenue per employee
$1.6 M
Profit per employee
$854 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-27M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-16M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-22M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-28M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-30M$0MFY22Fiscal year ending Dec 2023: revenue —, net income $-46M—FY23Fiscal year ending Dec 2024: revenue $43M, net income $-18M$43MFY24Fiscal year ending Dec 2025: revenue $312M, net income $163M$312MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$312M+617.1%$150M$163M52.3%
Dec 2024$43M—$-22M$-18M-41.2%
Dec 2023——$-49M$-46M—
Dec 2022$0M-63.2%$-31M$-30M-42428.6%
Dec 2021$0M-20.8%$-29M$-28M-14847.4%
Dec 2020$0M-14.3%$-27M$-22M-9179.2%
Dec 2019$0M-34.9%$-21M$-16M-5867.9%
Dec 2018$0M—$-27M$-27M-6239.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$175M$2M$173M$2.04—
Dec 2024$-51M$0M$-51M$-0.30—
Dec 2023$-38M$0M$-39M$-0.91—
Dec 2022$-24M$0M$-25M$-0.74—
Dec 2021$-21M$1M$-23M$-0.75—
Dec 2020$-22M$0M$-22M$-0.77—
Dec 2019$-15M$0M$-15M$-1.80—
Dec 2018$-24M$0M$-24M$-1.51—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$412M
Net income, trailing 12 months
$64M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $13M—Dec ’24Three months to Mar 2025: revenue $39M, net income $21M$39MMar ’25Three months to Jun 2025: revenue $40M, net income $20M$40MJun ’25Three months to Sep 2025: revenue $104M, net income $109M$104MSep ’25Three months to Dec 2025 (from the annual report): revenue $129M, net income $14M$129MDec ’25Three months to Mar 2026: revenue $127M, net income $39M$127MMar ’26Three months to Jun 2026: revenue $102M, net income $26M$102MJun ’26Three months to Sep 2026: revenue $55M, net income $-15M$55MSep ’26

Latest quarter to Sep 2026: revenue $55M (-47.7% on a year earlier), net income $-15M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of CorMedix Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$312 M
Operating income
$150 M
Net income
$163 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$826 M
Total liabilities
$421 M
Total equity
$405 M

As of December-2025

Top 100 institutional investors in CorMedix Inc.#

As of Sep 30, 2026
189 institutions held 46.6 M shares (about 58.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 37.1%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in CorMedix Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.6,453,154+129,043 (+2.04%)8.11%$50 MNov 13, 2026
2Deep Track Capital, LP6,274,0760 (0.00%)7.89%$48 MNov 16, 2026
3Vanguard Capital Management LLC3,051,570-83,505 (-2.66%)3.84%$23 MNov 13, 2026
4American Century Companies Inc2,722,920+2,377,579 (+688.47%)3.42%$21 MNov 12, 2026
5State Street Corp2,637,468+320,623 (+13.84%)3.32%$20 MNov 12, 2026
6UBS Group AG2,253,235+375,295 (+19.98%)2.83%$17 MNov 10, 2026
7Geode Capital Management, LLC1,909,979-37,035 (-1.90%)2.40%$15 MNov 6, 2026
8Royce & Associates LP1,659,947-516,415 (-23.73%)2.09%$13 MNov 9, 2026
9Oberweis Asset Management Inc/1,322,570-1,345 (-0.10%)1.66%$10 MNov 16, 2026
10Goldman Sachs Group Inc1,249,382+782,989 (+167.88%)1.57%$10 MNov 16, 2026
11Marshall Wace, LLP1,195,422+415,887 (+53.35%)1.50%$9 MNov 13, 2026
12Alyeska Investment Group, L.P.850,0000 (0.00%)1.07%$7 MNov 16, 2026
13Armistice Capital, LLC836,000+336,000 (+67.20%)1.05%$6 MNov 16, 2026
14Vanguard Portfolio Management LLC730,455+21,851 (+3.08%)0.92%$6 MNov 13, 2026
15Trexquant Investment LP719,148+95,351 (+15.29%)0.90%$6 MNov 16, 2026
16Northern Trust Corp718,296-38,134 (-5.04%)0.90%$6 MNov 16, 2026
17Morgan Stanley641,157+217,816 (+51.45%)0.81%$5 MNov 13, 2026
18Charles Schwab Investment Management Inc616,302-1,870 (-0.30%)0.77%$5 MNov 16, 2026
19HRT Financial LP610,228-15,330 (-2.45%)0.77%$5 MNov 13, 2026
20Hennion & Walsh Asset Management, Inc.536,909+98,280 (+22.41%)0.68%$4 MOct 13, 2026
21Bridgeway Capital Management, LLC459,223+25,091 (+5.78%)0.58%$4 MNov 16, 2026
22Vanguard Fiduciary Trust Co448,511-35,811 (-7.39%)0.56%$3 MNov 13, 2026
23Kennedy Capital Management LLC407,703-11,581 (-2.76%)0.51%$3 MNov 13, 2026
24Bank of New York Mellon Corp372,274-23,633 (-5.97%)0.47%$3 MNov 5, 2026
25Raymond James Financial Inc359,047-87,095 (-19.52%)0.45%$3 MNov 12, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in CorMedix Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26First Trust Advisors LP342,855+294,509 (+609.17%)0.43%$3 MNov 12, 2026
27D. E. Shaw & Co., Inc.330,468+158,661 (+92.35%)0.42%$3 MNov 16, 2026
28Ameriprise Financial Inc274,503-1,784 (-0.65%)0.35%$2 MNov 16, 2026
29Empowered Funds, LLC268,323+25,091 (+10.32%)0.34%$2 MNov 13, 2026
30Wellington Management Group LLP263,406+47,611 (+22.06%)0.33%$2 MNov 16, 2026
31Jpmorgan Chase & Co262,755+195,340 (+289.76%)0.33%$2 MNov 12, 2026
32Steward Partners Investment Advisory, LLC234,292+1,677 (+0.72%)0.29%$2 MNov 13, 2026
33Principal Financial Group Inc217,939+26,998 (+14.14%)0.27%$2 MNov 2, 2026
34Commonwealth Equity Services, LLC212,135-2,725 (-1.27%)0.27%$2 MNov 2, 2026
35Quantinno Capital Management LP197,568+57,530 (+41.08%)0.25%$2 MNov 13, 2026
36Nuveen, LLC183,428-1,846 (-1.00%)0.23%$1 MNov 10, 2026
37Susquehanna International Group, LLP174,658-144,310 (-45.24%)0.22%$1 MNov 16, 2026
38Two Sigma Investments, LP159,965+119,106 (+291.50%)0.20%$1 MNov 16, 2026
39Bank Of America Corp /de/158,462+7,806 (+5.18%)0.20%$1 MNov 16, 2026
40Private Advisor Group, LLC154,755-260,651 (-62.75%)0.19%$1 MNov 10, 2026
41Swiss National Bank146,800+8,000 (+5.76%)0.18%$1 MNov 12, 2026
42Wingate Wealth Advisors, Inc.128,002-500 (-0.39%)0.16%$1 MOct 26, 2026
43Profund Advisors LLC127,465+104,629 (+458.18%)0.16%$1 MOct 29, 2026
44Palisades Investment Partners, LLC122,188-304,355 (-71.35%)0.15%$1 MNov 3, 2026
45UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC107,049-6,691 (-5.88%)0.13%$1 MNov 16, 2026
46Credit Agricole S A104,0000 (0.00%)0.13%$1 MNov 13, 2026
47Franklin Templeton Inc101,175+77,739 (+331.71%)0.13%$1 MNov 12, 2026
48West Michigan Advisors, LLC97,500+31,500 (+47.73%)0.12%$1 MNov 9, 2026
49LPL Financial LLC94,191-43,975 (-31.83%)0.12%$1 MNov 6, 2026
50Rhumbline Advisers90,759-3,179 (-3.38%)0.11%$1 MNov 10, 2026
51Corient Private Wealth LP90,472-5,468 (-5.70%)0.11%$1 MNov 16, 2026
52AQR Capital Management LLC86,517-64,918 (-42.87%)0.11%$1 MNov 16, 2026
53Magnetar Financial LLC85,342+48,825 (+133.70%)0.11%$1 MNov 13, 2026
54Easterly Investment Partners LLC83,688+318 (+0.38%)0.11%$1 MNov 12, 2026
55California State Teachers Retirement System75,6390 (0.00%)0.10%$1 MNov 13, 2026
56Barclays PLC74,738+30,979 (+70.79%)0.09%$1 MNov 6, 2026
57Alps Advisors Inc73,550New0.09%$1 MNov 3, 2026
58Deutsche Bank AG\72,301-5,082 (-6.57%)0.09%$1 MNov 6, 2026
59Jump Financial, LLC65,910-114,117 (-63.39%)0.08%$1 MNov 13, 2026
60Birchview Capital, LP65,874New0.08%$1 MNov 13, 2026
61Price T Rowe Associates Inc /MD/62,0540 (0.00%)0.08%$0 MNov 16, 2026
62Alliancebernstein L.P.61,7800 (0.00%)0.08%$0 MNov 16, 2026
63Concurrent Investment Advisors, LLC61,483+18,083 (+41.67%)0.08%$0 MOct 16, 2026
64Man Group plc60,851New0.08%$0 MNov 16, 2026
65Citigroup Inc58,679-7,549 (-11.40%)0.07%$0 MNov 4, 2026
66Legal & General Group Plc58,5950 (0.00%)0.07%$0 MNov 16, 2026
67State of Alaska, Department of Revenue57,664-4,694 (-7.53%)0.07%$0 MOct 15, 2026
68Engineers Gate Manager LP54,678-11,878 (-17.85%)0.07%$0 MNov 16, 2026
69Renaissance Technologies LLC54,577New0.07%$0 MNov 12, 2026
70Pekin Hardy Strauss, Inc.54,0000 (0.00%)0.07%$0 MNov 2, 2026
71Canada Pension Plan Investment Board49,500+14,000 (+39.44%)0.06%$0 MNov 16, 2026
72CIBC Bancorp USA Inc.49,373+3,256 (+7.06%)0.06%$0 MNov 13, 2026
73VANGUARD ASSET MANAGEMENT, Ltd49,0400 (0.00%)0.06%$0 MNov 13, 2026
74ExodusPoint Capital Management, LP48,661-87,143 (-64.17%)0.06%$0 MNov 16, 2026
75Prudential Financial Inc46,344+34,074 (+277.70%)0.06%$0 MNov 16, 2026
76Lido Advisors, LLC44,7070 (0.00%)0.06%$0 MNov 4, 2026
77Entropy Technologies, LP43,155New0.05%$0 MNov 13, 2026
78Invesco Ltd.41,452-3,908 (-8.62%)0.05%$0 MNov 12, 2026
79Citadel Advisors LLC38,292-18,322 (-32.36%)0.05%$0 MNov 16, 2026
80SEI Investments Co35,9050 (0.00%)0.05%$0 MNov 10, 2026
81Bleakley Financial Group, LLC35,674New0.04%$0 MNov 13, 2026
82MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.35,609+1,265 (+3.68%)0.04%$0 MNov 16, 2026
83MetLife Investment Management, LLC35,368-6,145 (-14.80%)0.04%$0 MNov 16, 2026
84Creative Planning34,126-997 (-2.84%)0.04%$0 MNov 2, 2026
85Schonfeld Strategic Advisors LLC33,959+3,806 (+12.62%)0.04%$0 MNov 16, 2026
86Wealth Enhancement Advisory Services, LLC33,011-3,458 (-9.48%)0.04%$0 MOct 13, 2026
87Russell Investments Group, Ltd.32,646-7,146 (-17.96%)0.04%$0 MNov 6, 2026
88Sigma Planning Corp32,142+2,531 (+8.55%)0.04%$0 MOct 23, 2026
89Gryphon Financial Partners LLC31,001+942 (+3.13%)0.04%$0 MNov 4, 2026
90State Of Wisconsin Investment Board30,749+1,589 (+5.45%)0.04%$0 MNov 16, 2026
91VIRGINIA RETIREMENT SYSTEMS ET Al30,700-800 (-2.54%)0.04%$0 MOct 28, 2026
92HighTower Advisors, LLC30,425-2,230 (-6.83%)0.04%$0 MNov 10, 2026
93Beacon Pointe Advisors, LLC29,000+5,000 (+20.83%)0.04%$0 MNov 16, 2026
94Quantbot Technologies LP28,358+17,561 (+162.65%)0.04%$0 MNov 12, 2026
95Truist Financial Corp27,626+5,480 (+24.74%)0.03%$0 MOct 30, 2026
96Janus Henderson Group Ltd.26,900—0.03%$0 MNov 16, 2026
97Royal Capital Wealth Management, LLC24,500-4,000 (-14.04%)0.03%$0 MNov 16, 2026
98Vanguard Global Advisers, LLC24,245-3,473 (-12.53%)0.03%$0 MNov 13, 2026
99Royal Bank Of Canada23,656+804 (+3.52%)0.03%$0 MNov 16, 2026
100Wells Fargo & Company/mn23,438-45,558 (-66.03%)0.03%$0 MNov 16, 2026

All 189 institutional investors, with who bought and sold →

Mutual funds holding CorMedix Inc.#

104 funds hold shares worth $123 M (about 19.6% of the company). Since their previous reports 52 added shares and 41 sold, buying $3 M net.
Mutual funds holding CorMedix Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.23 M$17 M2.8%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.94 M$15 M2.4%0.02%+4.8%Jun 30, 2026
🇺🇸 Oberweis Micro-Cap FundOberweis Asset Management, Inc.1.28 M$10 M1.6%0.62%+9.9%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.824,083$6 M1.0%<0.01%−0.6%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC816,503$6 M1.0%0.02%+11%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors683,402$5 M0.86%0.04%newJun 30, 2026
🇺🇸 Pacer US Small Cap Cash Cows 100 ETFPacer Advisors, Inc.626,124$5 M0.79%0.13%+8.9%Jul 31, 2026
🇺🇸 Royce Small-Cap Opportunity FundRoyce & Associates, LP566,897$4 M0.71%0.32%+36%Jun 30, 2026
🇺🇸 Royce Small-Cap FundRoyce & Associates, LP562,746$4 M0.71%0.21%−6.8%Jun 30, 2026
🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc.549,805$4 M0.69%1.0%−0.8%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC381,249$3 M0.48%<0.01%−1.1%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.381,233$3 M0.48%0.02%+3.6%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.347,750$3 M0.44%0.01%−1.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors250,705$2 M0.32%0.13%+34%Jun 30, 2026
🇺🇸 Royce Capital Fund - Small-Cap PortfolioRoyce & Associates, LP245,212$2 M0.31%1.0%−14%Jun 30, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers243,232$2 M0.31%0.08%newJun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.220,892$2 M0.28%<0.01%−0.8%May 31, 2026
🇺🇸 VictoryShares Small Cap Free Cash Flow ETFVictory Capital Management Inc.202,848$2 M0.26%0.26%−59%Jun 30, 2026
🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors190,159$1 M0.24%0.13%−7.1%Jun 30, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC190,000$1 M0.24%0.11%newJun 30, 2026
🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC187,228$1 M0.24%0.06%+7.7%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.181,355$1 M0.23%0.02%+10%Jul 31, 2026
🇺🇸 Royce Small-Cap Value FundRoyce & Associates, LP146,768$1 M0.18%1.0%—Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC136,166$1 M0.17%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC139,411$1 M0.18%0.02%+16%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC111,717$1 M0.14%<0.01%+4.4%May 31, 2026
🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc.119,246$1 M0.15%0.13%−2.3%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC104,378$1 M0.13%0.04%newJun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.96,006$1 M0.12%0.08%+69%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors100,286$1 M0.13%<0.01%+2.5%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC99,068$1 M0.12%0.02%+11%Jul 31, 2026
🇺🇸 Easterly Snow Long/Short Opportunity FundEasterly Investment Partners LLC76,000$1 M0.10%0.58%newMay 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC80,596$1 M0.10%0.02%+0.3%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.70,036$1 M0.09%0.04%+2.9%May 31, 2026
🇺🇸 Vanguard U.S. Multifactor ETFThe Vanguard Group, Inc.69,653$1 M0.09%0.09%−30%May 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.71,301$1 M0.09%0.08%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC74,114$1 M0.09%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC46,045$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation47,500$0 M0.06%0.02%no changeJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.48,604$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.40,673$0 M0.05%<0.01%+1.2%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.39,264$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.38,378$0 M0.05%0.02%+18%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC39,401$0 M0.05%<0.01%+4.2%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC35,910$0 M0.05%0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC35,613$0 M0.04%0.02%+11%Jul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company31,191$0 M0.04%0.02%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.33,128$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC31,479$0 M0.04%<0.01%−7.4%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust26,402$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.26,500$0 M0.03%<0.01%−0.7%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC27,093$0 M0.03%<0.01%+3.2%Jul 31, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC24,695$0 M0.03%0.16%—Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC22,538$0 M0.03%0.02%−8.5%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors22,506$0 M0.03%<0.01%−0.8%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC21,390$0 M0.03%0.02%+18%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC21,100$0 M0.03%0.02%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC20,440$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC19,749$0 M0.02%0.10%+44%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC16,709$0 M0.02%0.06%+25%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS16,369$0 M0.02%0.02%+11%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC14,886$0 M0.02%0.02%+10%Jun 30, 2026
🇺🇸 Small-Cap Value PortfolioPacific Life Fund Advisors LLC14,879$0 M0.02%0.03%newJun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC14,188$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.11,715$0 M0.01%0.02%+9.7%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC12,076$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC11,457$0 M0.01%0.02%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.11,375$0 M0.01%0.02%+33%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC11,345$0 M0.01%0.02%+2.1%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC10,444$0 M0.01%0.02%+16%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION9,000$0 M0.01%<0.01%no changeMay 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC9,105$0 M0.01%0.02%+19%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.8,888$0 M0.01%<0.01%+9.4%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC8,301$0 M0.01%0.02%no changeJul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS6,881$0 M<0.01%0.02%+16%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management6,562$0 M<0.01%0.02%no changeJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC6,371$0 M<0.01%0.04%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC6,006$0 M<0.01%<0.01%+28%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.5,357$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.5,724$0 M<0.01%<0.01%−12%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC5,497$0 M<0.01%0.02%−7.3%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC5,030$0 M<0.01%0.02%+7.2%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC4,992$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors4,403$0 M<0.01%<0.01%−25%May 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC4,924$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC3,494$0 M<0.01%0.02%+8.7%May 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC3,654$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,296$0 M<0.01%<0.01%−36%Jun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC2,762$0 M<0.01%<0.01%−40%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC2,733$0 M<0.01%<0.01%−41%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC2,648$0 M<0.01%<0.01%−5.0%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,595$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,791$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,897$0 M<0.01%<0.01%+11%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,796$0 M<0.01%<0.01%+1.8%Jun 30, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC1,679$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc.1,664$0 M<0.01%<0.01%+14%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,457$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,209$0 M<0.01%<0.01%+2.0%Jun 30, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC889$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at CorMedix Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$513 K
2 purchases, 2 insiders
Sold, 12 months
$2.3 M
7 sales, 4 insiders
Net, 12 months
-$1.8 M
open market only
Insiders on file
35
since
$513 K-$2.2 M$0Nov 2023: bought $4 K (1 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $20 K (2 trades), sold $0 (0 trades)Mar 2024: bought $51 K (1 trades), sold $0 (0 trades)MarOct 2024: bought $15 K (1 trades), sold $0 (0 trades)Nov 2024: bought $0 (0 trades), sold $1.6 M (1 trades)NovSep 2025: bought $0 (0 trades), sold $2.2 M (6 trades)Oct 2025: bought $276 K (1 trades), sold $0 (0 trades)OctNov 2025: bought $0 (0 trades), sold $604 K (2 trades)Dec 2025: bought $0 (0 trades), sold $2.0 M (5 trades)DecJan 2026: bought $0 (0 trades), sold $69 K (1 trades)Nov 2026: bought $513 K (2 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
CorMedix Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Myron KaplanDirectorBuy+25,000$4.880$122 K256,487Form 4
filed Joseph TodiscoChief Executive Officer, DirectorBuy+80,000$4.890$391 K854,749Form 4
filed Janet DillioneDirectorOption exercise+48,909——117,835Form 4
filed Kaufman Beth ZelnickChief Legal OfficerShares withheld for tax-8,424$8.300$70 K260,684Form 4
filed Elizabeth HurlburtChief Operating OfficerShares withheld for tax-8,076$8.300$67 K270,463Form 4
filed Susan BlumChief Financial OfficerShares withheld for tax-8,424$8.300$70 K124,315Form 4
filed Joseph TodiscoChief Executive Officer, DirectorGrant or award+77,156——774,749Form 4
filed Kaufman Beth ZelnickChief Legal OfficerGrant or award+36,006——269,108Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: CorMedix Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
14.2 M
17.9% of shares · 8.44 days to cover
Buybacks, Q3 2026
$0M
Q3 2026
Shares sold short, last 24 reportsAll stocks →
CorMedix Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0M
Q2 2026Q2 2026$6.4M
Q1 2026Q1 2026$11.1M
Q3 2025Q3 2026$0M
Q2 2025Q2 2026$0M
Q1 2025Q1 2026$0M

Fails to deliver

  • : 13,428 shares at $8.20
  • : 959 shares at $8.00
  • : 726 shares at $7.94
  • : 36,938 shares at $7.57
  • : 55 shares at $7.38

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

CorMedix Inc. scorecard#

Passes 14 of the 17 checks that could be worked out: strongest in valuation (5 of 5), weakest in financial health (2 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation5 of 5
    • ✓P/E below its peers' median10.2×P/E 10.2× against Biotechnology's median of 17.5×.
    • ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median1.6×Price to sales 1.6× against Biotechnology's median of 8.7×.
    • ✓Free cash flow yield above 5%26.5%Free cash flow is 26.5% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield9.8%Earnings yield 9.8% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'No revenue growth over three years on file.
  • Growth3 of 3
    • ✓Revenue grew in the newest year617.1%Revenue up 617.1% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✓Earnings per share grew in the newest year2.04 vs -0.30Diluted EPS 2.04 in fiscal 2025 against -0.30 the year before (report's currency).
    • ✓Net income higher than five years earlier$163 M$163 M in fiscal 2025 against -$22 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability4 of 5
    • ✓Profitable in the newest year$163 MNet income $163 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median48.2%48.2% against Biotechnology's median of -60.5% (243 companies).
    • ✓Return on equity above 15%66.6%66.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier48.2%48.2% in fiscal 2025 against -43742.9% in 2022.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities2.1×Current ratio 2.11 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone1.89Z-score 1.89 (grey zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year35.6%Diluted shares up 35.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from CorMedix Inc.'s statements, beside the median of Biotechnology.

CorMedix Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin48.2%-60.5%
Net margin52.3%-68.9%
Return on equity66.6%-61.0%
Revenue growth617.1%15.8%
Free cash flow margin55.4%-61.5%

5of 8on the Piotroski tests of financial strength

  • The share count rose 35.6% in the year.
  • Goodwill and intangibles ($409 million) exceed shareholders' equity ($405 million).

CorMedix Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CorMedix Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue31243r—0.10.20.20.30.40.30.2
Cost of revenue223.0r—0.00.10.20.40.40.10.4r
Gross profit27640r—0.10.00.0−0.10.00.2−0.1
Research and development193.9r1311131311192416
Selling, general and administrative——362016149.98.1——
Selling and marketing3829r18———————
General and administrative6830r18————8.18.78.9
Operating expenses12663r4931292721273325
Total costs and expenses————3.0—————
Operating income150−22r−49−31−29−27−21−27−33−25
Interest and finance income3.82.6r2.7——0.10.30.00.10.1
Interest expense and finance costs2.80.0r0.00.00.00.00.80.00.00.0
Net interest income—1.4————————
Other non-operating income (expense)−0.13.0r2.60.3−0.00.0−0.50.0−0.1—
Income before tax150−19r−46−30−29−27−21−27−33−25
Income tax−13−1.4r—−0.6−1.3−5.2−5.1———
Income from continuing operations1.7—————————
Net income including minority interests————−28−22−16———
Minority interests' share of net income————2822————
Net income attributable to shareholders163−18r−46−30−28−22−16−27−33−25
Earnings per share, basic2.25-0.30-0.91-0.74-0.75-0.77-1.80-1.51r-0.60-0.65
Earnings per share, diluted2.04-0.30-0.91-0.74-0.75-0.77-1.80-1.51r-0.60-0.65
Shares, weighted average (basic)0.10.1r514038—————
Shares, weighted average (diluted)0.10.1r514038292418r5538
Balance sheet
Cash and cash equivalents14541r444353421618108.1
Short-term investments3.711r3216124.41201.612
Receivables17152r—————0.00.10.0
Inventory307.6r2.1—0.00.10.30.40.60.2
Other current assets183.6r0.90.60.81.40.40.40.40.4
Current assets367115r7960664829191322
Property, plant and equipment6.01.8r1.91.61.50.10.1r0.20.20.1
Right-of-use (leased) assets3.00.5r0.60.80.91.00.0———
Goodwill30—————————
Other intangible assets3791.8r————————
Total assets826119r8262694929191322
Accounts payable7.91.7r4.32.22.21.11.02.61.81.6
Current liabilities17434r116.35.34.25.87.86.34.1
Lease liabilities (non-current)2.30.3r0.50.70.80.90.00——
Total liabilities42134r127.06.15.15.8146.34.1
Retained earnings−177−340r−322−275−246−217−195−179−152−119
Shareholders' equity40585r70r556344244.9r7.218
Total liabilities and equity826119r8262694929191322
Shares outstanding7964554338342622r7140
Cash-flow statement
Share-based compensation146.1r5.54.15.02.52.41.11.71.3
Cash from operating activities175−51r−38−24−21−22−15−24−29−22
Capital expenditure−2.3−0.1r−0.3−0.2−1.4−0.1−0.0−0.0−0.2−0.1
Acquisitions, net of cash acquired−309—————————
Cash from investing activities−30821r−17−3.7−9.17.4−121.61011
Shares issued7.819r131841181500.30
Cash from financing activities23826r561842402629217.1
Exchange-rate effect on cash—−0.0r0.0−0.0−0.00.0−0.0−0.00.00.0
Change in cash105−3.1r0.4−101126−1.37.22.3−3.8
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What CorMedix Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product Sales, Net(total)$304 M98%
  • DefenCath$259 M83%
  • Melinta Portfolio$46 M15%
  • Contract revenue$7 M2.4%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at CorMedix Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$6.1 M
Joseph Todisco
Other top executives, average
$3.8 M
the CEO earned 1.6× this
$100 invested is now
$276
CorMedix Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Joseph Todisco$6.1 M$8.9 M$3.8 M$276
2024Joseph Todisco$2.4 M$5.4 M$1.1 M$192
2023Joseph Todisco$2.5 M$1.9 M$1.2 M$89

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at CorMedix Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling

Auditor changed 2 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 4 · New debt 1 · Unregistered share sale 4 · Shareholder vote 2 · Results announced 12

CorMedix Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officersResults announced8-K
Results announced8-K
Results announced8-K
Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share saleResults announced8-K
Shareholder vote8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 acquisitions, $477 M paid where reported · 1 private funding rounds before listing

Businesses it acquired

Acquisitions by CorMedix Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Acquisition of Melinta2025—$454 M—Annual report
Toprol XL2025—$23 M—Annual report

Private share sales · funding history

Private share sales of CorMedix Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2009$3 MNo. 1$2 to $10 million19equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by CorMedix Inc.#

$650 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$650 K
#526 among companies on value.today
Own lobbyists
Yes
files its own reports
Firms hired
0
in 2025
2026 so far
$800 K
  • Health Issues4 reports
CorMedix Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$800 K$800 K3
2025$650 K$650 K4
2024$870 K$870 K10
2023$670 K$590 K12
2021$0—2
2020$0—4
2019$0—4
2018$30 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “CorMedix Inc.”, “Cormedix” and “CorMedix, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

FDA drug approvals: CorMedix Inc.#

1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2023.

Approvals held
1
New molecular entities
1
New uses approved
0
efficacy supplements
Generics
0
1 new drugs, 0 biologics
CorMedix Inc.: latest FDA approvals
ApprovedDrugKind
2023-11-15Defencathnew moleculeHeparin Sodium, Taurolidine · NDA214520New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (CORMEDIX), so they follow acquisitions

Discuss CorMedix Inc.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    CorMedix Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $55 million (down 48% from a year earlier) and a net loss of $15 million.

  • Results announced on 2 November 2026automatic update · Nov 2, 2026

    CorMedix Inc. announced results on 2 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $55 million (down 48% from a year earlier) and a net loss of $15 million.

  • Mutual funds: 104 funds hold $123 millionautomatic update · Jul 31, 2026

    104 mutual funds in 1 country hold shares of CorMedix Inc. worth $123 million, about 19.6% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 52 funds added shares and 41 sold; on balance they bought $3 million. Share splits are not counted as trading.

How CorMedix Inc. compares in Biotechnology

  • Market cap$652 M · higher than 62% of 726
  • Revenue$312 M · higher than 82% of 647
  • Net margin15.5% · higher than 82% of 408
  • Revenue growth617.1% · higher than 95% of 438
  • P/E ratio10.2× · lower than 73% of 100
  • Price / sales1.6× · lower than 89% of 339
  • Price / book1.6× · lower than 65% of 534
  • FCF yield26.5% · highest of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
CorMedix Inc.🇺🇸$652 M10.2×15.5%+617.1%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of February 28, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CorMedix Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CorMedix Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CorMedix Inc.? Suggest a correction